Bionco Diagnostics Information

BioncoDx is developing a non-invasive liquid biopsy test for lung cancer - affordable, easy to collect, and designed to reach the millions who can't access today's screening methods. Today’s screening methods can be expensive, inconvenient, and poorly utilized, leaving many at-risk individuals unscreened. Building on metabolite-based diagnostic technology developed by NIH/NCI researchers and academic collaborators, BioncoDx has assembled a world-class scientific, clinical, and commercial team to advance a more accessible, effective, and lower-cost screening platform. The company’s initial focus is lung cancer, with longer-term potential across multiple cancer types and applications in detection, prognosis, patient stratification, and companion diagnostics.